Previous 10 | Next 10 |
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress PR Newswire – Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rap...
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy PR Newswire – Phase 1b Safety and Efficacy Data for Rezpegaldesleukin in Moderate to Severe Atopic Dermatitis to be...
2023-09-27 12:47:12 ET More on Nektar Therapeutics Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript Data Errors Could Give Nektar Therapeutics A New Lease On Life Nektar reportedly sues Lilly for bungling clinical data on dermo drug Seeking Alpha...
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer PR Newswire SAN FRANCISCO , Sept. 27, 2023 /PRNewswire/ -- Nektar Therapeu...
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis PR Newswire New Statistically Significant Results Reported for Clinical Efficacy Endpoints of BSA, DLQI and POEM from Phase 1b Study ...
2023-09-11 14:22:11 ET Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to tradit...
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th PR Newswire SAN FRANCISCO , Sept. 6, 2023 /...
2023-09-04 04:30:00 ET Summary For the week, the S&P 500 was up 2.5%. We are now just 1.6% below the 2023 high-water mark, set on July 31. The market entered a Golden Cross configuration on February 2, 2023. A recession remains a distinct possibility, especially if the Fed...
2023-08-21 06:45:00 ET Summary After making a new 2023 high on July 31, the market is now in the process of consolidating its gains and expanding its participation. The best performer last week was Volatility, as investors looked for ways to protect their gains from further downsi...
2023-08-14 13:30:00 ET Summary After making a new 2023 high on July 31, the market is now in the process of consolidating its gains and expanding its participation. The Death Cross ended on February 2, 2023. We are now in a Golden Cross configuration, with the 50-day above the 200...
News, Short Squeeze, Breakout and More Instantly...
Nektar Therapeutics Reports First Quarter 2024 Financial Results PR Newswire SAN FRANCISCO , May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2024 . Cash and ...
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets PR Newswire SAN FRANCISCO , May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results fo...
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire SAN FRANCISCO ,...